Alnylam Pharma (ALNY) Misses Q1 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Jefferies Cuts Price Target on Alnylam Pharma (ALNY) Following 1Q
May 3, 2016 9:40 AM EDTJefferies maintained a Buy rating on Alnylam Pharmaceuticals (NASDAQ: ALNY), and cut the price target to $119.00 (from $122.00), following the company's 1Q earnings report. ALNY reported 1Q16 revenues of $7.3M, ahead of consensus estimates of 7.8M. The company ended the quarter with... More
Leerink Cuts Alnylam (ALNY) PT to $107
May 3, 2016 8:14 AM EDTLeerink Partners analyst, Michael Schmidt, recapped the Alnylam Pharmaceuticals (NASDAQ: ALNY) pipeline update from 1Q results and cut his price target but maintained his Outperform rating. The PT drops to $107 from $120 but still offers 55% upside.
Pipeline updates: (1) Enrollment of the Revusiran Ph III trial in... More
